StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Tuesday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.5 %

NASDAQ NURO opened at $4.02 on Tuesday. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $6.00. The stock has a market cap of $8.08 million, a P/E ratio of -0.64 and a beta of 2.28. The stock’s fifty day moving average price is $3.60 and its 200-day moving average price is $3.84.

NeuroMetrix (NASDAQ:NURO) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The company had revenue of $0.77 million during the quarter.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.